Eric Bruckert Selected Research

HDL3 Lipoproteins

1/2016	Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis.
8/2003	Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric Bruckert Research Topics

Disease

37	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2003
33	Atherosclerosis 01/2022 - 03/2002
27	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 05/2022 - 06/2003
14	Dyslipidemias (Dyslipidemia) 05/2022 - 08/2003
14	Hypercholesterolemia 05/2022 - 03/2002
13	Homozygous Familial Hypercholesterolemia 01/2021 - 05/2002
12	Stroke (Strokes) 01/2021 - 01/2006
11	Coronary Disease (Coronary Heart Disease) 12/2021 - 06/2003
11	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 10/2004
9	Ischemic Stroke 01/2022 - 05/2014
9	Insulin Resistance 09/2011 - 05/2002
8	Pancreatitis 01/2020 - 07/2008
7	Inflammation (Inflammations) 12/2021 - 02/2004
7	Hypertriglyceridemia 10/2020 - 01/2003
6	Myocardial Infarction 10/2020 - 02/2004
6	Atherosclerotic Plaque (Atheroma) 09/2019 - 01/2003
5	Hypertension (High Blood Pressure) 01/2022 - 09/2002
5	Myalgia 01/2021 - 09/2003
5	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2012
5	Acute Coronary Syndrome 12/2020 - 01/2003
5	Inborn Genetic Diseases (Disease, Hereditary) 05/2020 - 03/2015
5	Abdominal Obesity 07/2018 - 10/2004
5	Coronary Artery Disease (Coronary Atherosclerosis) 07/2016 - 03/2008
5	Fibrosis (Cirrhosis) 10/2014 - 02/2004
4	Transient Ischemic Attack 01/2022 - 05/2014
4	Prediabetic State (Prediabetes) 01/2021 - 09/2011
4	Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial) 10/2020 - 11/2002
4	Xanthomatosis (Xanthoma) 01/2019 - 12/2013
4	Hyperlipidemias (Hyperlipidemia) 02/2017 - 08/2003
3	Chronic Renal Insufficiency 10/2021 - 03/2014
3	Muscular Diseases (Myopathy) 01/2021 - 05/2015
3	Costello Syndrome 10/2020 - 01/2018
3	Carotid Artery Diseases 01/2020 - 03/2009
3	Neoplasms (Cancer) 12/2015 - 02/2004
3	Obesity 10/2014 - 05/2002
3	Fatty Liver 10/2014 - 07/2008
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2022 - 01/2020
2	Infections 10/2021 - 01/2019
2	Body Weight (Weight, Body) 05/2020 - 11/2017
2	Pathologic Constriction (Stenosis) 01/2020 - 01/2020
2	Overweight 07/2018 - 03/2004
2	Diabetes Mellitus 01/2018 - 02/2011
2	Non-alcoholic Fatty Liver Disease 02/2010 - 07/2008
2	Rupture 07/2003 - 01/2003
1	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 05/2022
1	Aortic Valve Stenosis (Aortic Stenosis) 12/2021

Drug/Important Bio-Agent (IBA)

48	oxidized low density lipoproteinIBA 05/2022 - 03/2002
48	LDL CholesterolIBA 05/2022 - 06/2003
42	LipidsIBA 12/2021 - 03/2002
29	CholesterolIBA 12/2021 - 05/2002
25	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 05/2002
24	Triglycerides (Triacylglycerol)IBA 05/2022 - 01/2003
21	Lipoproteins (Lipoprotein)IBA 01/2021 - 08/2003
17	HDL CholesterolIBA 01/2021 - 11/2003
13	ApolipoproteinsIBA 01/2020 - 06/2003
9	Apolipoproteins B (ApoB)IBA 01/2020 - 06/2003
9	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020 - 10/2004
8	Biomarkers (Surrogate Marker)IBA 09/2019 - 04/2006
7	LDL Receptors (LDL Receptor)IBA 01/2020 - 06/2003
6	Ezetimibe (Zetia)FDA Link 01/2022 - 05/2002
6	Proprotein Convertase 9IBA 01/2022 - 06/2003
6	HDL LipoproteinsIBA 10/2020 - 08/2003
6	alirocumabIBA 09/2020 - 12/2015
5	Lipoprotein(a)IBA 12/2021 - 08/2012
5	Glucose (Dextrose)FDA LinkGeneric 12/2020 - 06/2004
5	Phytosterols (Plant Sterols)IBA 01/2018 - 09/2007
5	Cholesterol Esters (Cholesteryl Esters)IBA 03/2008 - 03/2002
4	Apolipoprotein A-I (Apolipoprotein A1)IBA 10/2020 - 11/2006
4	Biological ProductsIBA 01/2020 - 01/2009
4	Atorvastatin (Lipitor)FDA Link 09/2019 - 05/2002
4	Pharmaceutical PreparationsIBA 09/2019 - 09/2011
4	Proteins (Proteins, Gene)FDA Link 07/2018 - 08/2003
4	Insulin (Novolin)FDA Link 07/2008 - 05/2002
3	Apolipoproteins E (ApoE)IBA 05/2022 - 12/2011
3	CalciumIBA 12/2021 - 07/2018
3	BMS201038IBA 01/2021 - 08/2014
3	Creatine Kinase (Creatine Phosphokinase)IBA 01/2020 - 12/2005
3	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2019 - 01/2003
3	Fibric Acids (Fibrates)IBA 02/2011 - 08/2003
3	C-Reactive ProteinIBA 07/2008 - 06/2006
2	evolocumabIBA 01/2022 - 06/2014
2	Antisense OligonucleotidesIBA 10/2020 - 01/2020
2	ISIS 304801IBA 10/2020 - 01/2019
2	Scavenger Receptors (Scavenger Receptor)IBA 11/2016 - 08/2003
2	Adenosine Triphosphate (ATP)IBA 11/2016 - 01/2006
2	HDL3 LipoproteinsIBA 01/2016 - 08/2003
2	omega-Chloroacetophenone (Mace)IBA 03/2014 - 10/2005
2	Niacin (Nicotinic Acid)FDA LinkGeneric 09/2010 - 06/2010
2	Transaminases (Aminotransferases)IBA 02/2010 - 07/2008
2	Rosiglitazone (Avandia)FDA Link 02/2010 - 07/2008
2	Blood Glucose (Blood Sugar)IBA 10/2008 - 06/2006
2	Fluvastatin FDA Link 10/2005 - 07/2003
2	Matrix Metalloproteinases (MMPs)IBA 02/2004 - 07/2003
1	ALN-PCSIBA 01/2022
1	AnticoagulantsIBA 01/2022
1	Small Interfering RNA (siRNA)IBA 01/2022

Therapy/Procedure

34	Therapeutics 01/2022 - 05/2002
13	Blood Component Removal (Apheresis) 01/2021 - 05/2002
4	Secondary Prevention 01/2022 - 06/2010
2	Drug Therapy (Chemotherapy) 10/2018 - 09/2014